153 related articles for article (PubMed ID: 6573955)
1. Sensitivity of bone marrow hematopoietic colony-forming cells from mice, dogs, and humans to carminomycin, marcellomycin, aclacinomycin A, and N,N-dibenzyldaunorubicin and its relationship to clinical toxicity.
Marsh JC; Brown BJ; Nierenburg MM
Cancer Res; 1983 Jun; 43(6):2962-6. PubMed ID: 6573955
[TBL] [Abstract][Full Text] [Related]
2. Correlation of hematologic toxicity of antineoplastic agents with their effects on bone marrow stem cells: interspecies studies using an in vivo assay.
Marsh JC
Exp Hematol; 1985; 13 Suppl 16():16-22. PubMed ID: 3987835
[TBL] [Abstract][Full Text] [Related]
3. [Colony-forming ability of bone marrow hematopoietic cells in mice with transplanted leukemia during administration of carminomycin].
Kozinets GI; Ivanova LE; Khanykova OK; Kuznetsova TV; Rudneva NA
Eksp Onkol; 1984; 6(5):59-62. PubMed ID: 6510345
[TBL] [Abstract][Full Text] [Related]
4. [Hemopoietic precursor cells during the development of carminomycin resistance].
Kozinets GI; Ivanova LE; Kuznetsova TV; Khanykova OK
Eksp Onkol; 1985; 7(1):48-52. PubMed ID: 3979340
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the sensitivities of human, canine, and murine hematopoietic precursor cells to adriamycin and N-trifluoroacetyladriamycin-14-valerate.
Marsh JC
Cancer Res; 1979 Feb; 39(2 Pt 1):360-4. PubMed ID: 761207
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of some anthracycline antibiotics in an in vivo model for studying drug-induced human leukemia cell differentiation.
Schwartz EL; Brown BJ; Nierenburg M; Marsh JC; Sartorelli AC
Cancer Res; 1983 Jun; 43(6):2725-30. PubMed ID: 6573951
[TBL] [Abstract][Full Text] [Related]
7. The sensitivities of human and murine hemopoietic cells exposed to cytotoxic drugs in an in vivo culture system.
Gordon MY; Blackett N
Cancer Res; 1976 Aug; 36(8):2822-6. PubMed ID: 1277192
[TBL] [Abstract][Full Text] [Related]
8. Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro.
Seeber S; Loth H; Crooke ST
J Cancer Res Clin Oncol; 1980; 98(2):109-18. PubMed ID: 6938517
[TBL] [Abstract][Full Text] [Related]
9. In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia.
Marie JP; Thevenin D; Zittoun R
Nouv Rev Fr Hematol (1978); 1985; 27(3):163-7. PubMed ID: 3862071
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships for the induction of differentiation of HL-60 human acute promyelocytic leukemia cells by anthracyclines.
Schwartz EL; Sartorelli AC
Cancer Res; 1982 Jul; 42(7):2651-5. PubMed ID: 6952957
[TBL] [Abstract][Full Text] [Related]
11. Comparative ultrastructural studies of nucleoli of tumor cells treated with adriamycin and the newer anthracyclines, carminomycin and marcellomycin.
Daskal Y; Woodard C; Crooke ST; Busch H
Cancer Res; 1978 Feb; 38(2):467-73. PubMed ID: 202387
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic precursor cells in mice treated with 4-demethoxydaunorubicin and doxorubicin.
Massa G; Bogliolo G; D'Amore F; Muzzulini C; Ghio R; Pannacciulli I
J Natl Cancer Inst; 1982 Jun; 68(6):971-6. PubMed ID: 6953276
[TBL] [Abstract][Full Text] [Related]
13. Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro.
Lin H; She YH; Cassileth BR; Sirotnak F; Cunningham Rundles S
Int Immunopharmacol; 2004 Jan; 4(1):91-9. PubMed ID: 14975363
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship between anthracycline-induced differentiation and inhibition of glycoprotein synthesis in Friend erythroleukemia cells.
Schaefer A; Dahle M; Radenz G; Steinheider G; Marquardt H
Leukemia; 1991 Feb; 5(2):95-100. PubMed ID: 2020200
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of methotrexate, two nonclassic folic acid antagonists, and cytarabine on hematopoietic precursor cells.
Marsh JC
Cancer Treat Rep; 1982 Mar; 66(3):499-504. PubMed ID: 6460555
[TBL] [Abstract][Full Text] [Related]
16. A phase I and clinical pharmacology study of intravenously administered carminomycin in cancer patients in the United States.
Comis RL; Issell BF; Pittman K; Ginsberg SJ; Rudolph A; Aust JC; DiFino SM; Tinsley RW; Poiesz BJ; Crooke ST
Cancer Res; 1982 Jul; 42(7):2944-8. PubMed ID: 7083181
[TBL] [Abstract][Full Text] [Related]
17. [Comparative characteristics of the antitumor and immunodepressive activity of carminomycin on the L-1210 experimental model].
Berezina TA; Uteshev BS
Antibiotiki; 1979 Oct; 24(10):767-71. PubMed ID: 496420
[TBL] [Abstract][Full Text] [Related]
18. [Cytological characteristics of carminomycin-resistant P-388 lymphoid leukosis].
Kozinets GI; Ivanova E; Kuznetsova TV; Khanykova OK; Levina NV
Eksp Onkol; 1985; 7(4):60-4, 76. PubMed ID: 4042959
[TBL] [Abstract][Full Text] [Related]
19. [New anthracycline antibiotics and derivatives].
Tatsuta K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2640-52. PubMed ID: 6594977
[TBL] [Abstract][Full Text] [Related]
20. Interaction of anthracyclines with covalently closed circular DNA.
Mong S; DuVernay VH; Strong JE; Crooke ST
Mol Pharmacol; 1980 Jan; 17(1):100-4. PubMed ID: 6155600
[No Abstract] [Full Text] [Related]
[Next] [New Search]
